Department of Pediatrics, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
Department of Pediatric Hematology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
Turk J Haematol. 2013 Sep;30(3):290-9. doi: 10.4274/Tjh.2012.0094. Epub 2013 Sep 5.
Survival rates for childhood acute lymphoblastic leukemia (ALL) have significantly improved and late effects of therapy have been important in the follow-up of survivors. The objective of this study is to identify the endocrinological and cardiological late effects of ALL patients treated in our pediatric hematology unit.
Patients treated for ALL with BFM protocols after at least 5 years of diagnosis and not relapsed were included in the study. Endocrinological late effects (growth failure, obesity, insulin resistance, dyslipidemia, thyroid gland disorders, osteopenia/osteoporosis, and pubertal disorders) and cardiological late effects were evaluated. The study group was evaluated with anthropometric measurements, body mass index, and laboratory testing of fasting glucose, insulin, serum lipids, thyroid functions, and bone mineral densities. Echocardiography and pulsed wave Doppler imaging were performed for analysis of cardiac functions.
Of the 38 ALL survivors, at least 1 adverse event occurred in 23 (60%), with 8 of them (21%) having multiple problems. Six (16%) of the survivors were obese and 8 (21%) of them were overweight. Subjects who were overweight or obese at the time of diagnosis were more likely to be overweight or obese at last follow-up. Obesity was more frequently determined in patients who were younger than 6 years of age at the time of diagnosis. Insulin resistance was observed in 8 (21%) subjects. Insulin resistance was more frequently seen in subjects who had family history of type 2 diabetes mellitus. Hyperlipidemia was detected in 8 (21%) patients. Hypothyroidism or premature thelarche were detected in 2 children. Two survivors had osteopenia. Cardiovascular abnormalities occurred in one of the subjects with hypertension and cardiac diastolic dysfunction.
We point out the necessity of follow-up of these patients for endocrinological and cardiological late effects, since at least one adverse event occurred in most of our cases.
None declared.
儿童急性淋巴细胞白血病(ALL)的存活率有了显著提高,治疗的晚期效应在幸存者的随访中非常重要。本研究的目的是确定在我院儿科血液科接受治疗的 ALL 患者的内分泌和心脏晚期效应。
本研究纳入了至少在诊断后 5 年且未复发的接受 BFM 方案治疗的 ALL 患者。评估了内分泌系统(生长障碍、肥胖、胰岛素抵抗、血脂异常、甲状腺功能障碍、骨质疏松/骨量减少和青春期障碍)和心脏晚期效应。研究组通过人体测量学测量、体重指数和空腹血糖、胰岛素、血脂、甲状腺功能和骨矿物质密度的实验室检查进行评估。对心脏功能进行超声心动图和脉冲波多普勒成像检查。
38 名 ALL 幸存者中,至少有 1 名出现不良事件的有 23 名(60%),其中 8 名(21%)有多种问题。6 名(16%)幸存者肥胖,8 名(21%)超重。诊断时超重或肥胖的患者在最后一次随访时更有可能超重或肥胖。诊断时年龄小于 6 岁的患者更容易肥胖。8 名(21%)患者出现胰岛素抵抗。有 2 型糖尿病家族史的患者更易出现胰岛素抵抗。8 名(21%)患者血脂异常。2 名患儿出现甲状腺功能减退或性早熟。2 名幸存者骨密度减少。1 名高血压和舒张性心功能障碍患者出现心血管异常。
我们指出了对这些患者进行内分泌和心脏晚期效应随访的必要性,因为我们的大多数病例至少发生了 1 种不良事件。
无。